When was NEUROPHET founded?

NEUROPHET was founded in 2016 and raised its 1st funding round 3 years after it was founded.

Where is NEUROPHET located?

NEUROPHET is headquartered in Seoul, South Korea.

Who is the current CEO of NEUROPHET?

Junkil Been of NEUROPHET. They have also founded 1 company.

How many employees does NEUROPHET have?

As of Apr 30, 2026, the latest employee count at NEUROPHET is 80.

Is NEUROPHET a funded company?

NEUROPHET is a funded company, having raised a total of $24.4M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 26, 2019.

When was the latest funding round of NEUROPHET?

NEUROPHET's latest funding was a $***** Post IPO round on Apr 13, 2026, with participation from 2 investors. Its primary sector is Cognitive Computing. In South Korea, the Cognitive Computing sector has seen $48.8M in funding in 2026 to date.

Where does NEUROPHET rank among its competitors?

NEUROPHET ranks 1st amongst 75 active competitors, of which 30 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was NEUROPHET, which secured $21.5M in Apr, 2026.

Who are the top competitors of NEUROPHET?

NEUROPHET's top competitors include RapidAI, Cortechs.ai and icometrix. Among them, NEUROPHET secured the most recent funding round in April, 2026.

NEUROPHET - 2026 Company Profile, Team, Funding, Competitors & Financials

NEUROPHET is a public company based in Seoul (South Korea), founded in 2016 by Junkil Been. It operates as a Developer of AI-based simulation software for doctors and researchers in electrical brain stimulation. NEUROPHET has raised $24.4M in funding from investors like SBI Investment Korea, ES Investor and Samjin Pharm. The company has 75 active competitors, including 30 funded and 6 that have exited. Its top competitors include companies like RapidAI, Cortechs.ai and icometrix.

Company Details

Developer of AI-based simulation software for doctors and researchers in electrical brain stimulation. It is developing simulation software in neuro-engineering that is specialized for doctors and researchers in electrical brain stimulation (EBS). Its users can generate an individual 3D brain model by MRI, and simulate and analyze the potential effects of EBS in the various parameters of treatment in a clinical setting. It helps with full-automatic 3D brain model generation for each patient.

Website: www.neurophet.com/en
Social
Email ID: *****@neurophet.com
Phone Number: +82 **********

Key Metrics

Founded Year

2016

Location

Seoul, South Korea

Stage

Public

Total Funding

$24.4M in 5 rounds

Latest Funding Round

Post IPO, Apr 13, 2026, $*****

Investors

SBI Investment Korea & 19 more

Ranked

1^st among 75 active competitors

Employee Count

80 as on Apr 30, 2026

Similar Companies

Abridge Inc & 2372 more

Exit Details

Public

View NEUROPHET's full profile

NEUROPHET is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Neurofit Co., Ltd. CIN: 204-86-57415 , South Korea, Active	Mar 13, 2016	$1M - $10M (As on Dec 31, 2024)	-	-

NEUROPHET got listed on Jul 25, 2025.

Click here to take a look at NEUROPHET's IPO in detail

NEUROPHET has raised a total funding of $24.4M over 5 rounds. Its first funding round was on Nov 26, 2019. Its latest funding round was a Post IPO round on Apr 13, 2026 for $*****. 2 investors participated in its latest round. NEUROPHET has 20 institutional investors.

Here is the list of recent funding rounds of NEUROPHET:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 13, 2026	2571240	Post IPO	6324349	4300190	1567716	5014221
Mar 04, 2024	8423128	Series B	5183861	1728061	2502257	2243810
Nov 08, 2021	3753613	Series B	8316339	9746878	SBI Investment Korea & 5 more	5413876

Access funding benchmarks and valuations. Sign up today!

View details of NEUROPHET's funding rounds and investors

The founders of NEUROPHET is Junkil Been. Junkil Been is the CEO of NEUROPHET.

Here are the details of NEUROPHET's key team members:

Junkil Been: Co-Founder & Co-CEO of NEUROPHET.

View details of NEUROPHET's Founder profiles and Board Members

NEUROPHET's employee count trend

NEUROPHET has 80 employees as of Apr 26. Here is NEUROPHET's employee count trend over the years:

Uncover NEUROPHET's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NEUROPHET include RapidAI, Cortechs.ai and icometrix. Here is the list of Top 10 competitors of NEUROPHET, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	NEUROPHET 2016, Seoul (South Korea), Public	Developer of AI-based simulation software for doctors and researchers in electrical brain stimulation	$24.4M	Kolon Investments, Philips HealthWorks & 18 others	61/100
2nd	RapidAI 2012, San Mateo (United States), Series C	Developer of clinical AI platform enhancing medical imaging and stroke care	$100M	Lennertz, Vistacreditpartners & 2 others	57/100
3rd	Cortechs.ai 2001, San Diego (United States), Series C	Provider of AI-powered medical imaging analysis software	$9.07M	NIH, Vilas Ventures & 2 others	56/100
4th	icometrix 2011, Leuven (Belgium), Acquired	Provider of an AI based software for analysis of brain MRI images	$20.2M	Forestay Capital, Capricorn Partners & 9 others	56/100
5th	BrainSightAI 2019, Bengaluru (India), Seed	AI based platform offering connectomics for functional brain mapping	$6.66M	Pfizer, SAB Holding & 51 others	55/100
6th	heuron 2019, Incheon (South Korea), Series B	Provider of AI-based clinical diagnosis software for doctors	$13.4M	SBVA, Positive Investment & 2 others	53/100
7th	LVIS 2011, Palo Alto (United States), Series B	AI powered EEG analysis platform for neurological disease diagnosis	$18M	SK, SK Networks & 4 others	53/100
8th	Methinks 2016, Barcelona (Spain), Seed	Provider of AI and cloud-based software for the diagnosis of strokes	-	EIC Fund, Nina Capital & 3 others	51/100
9th	Omniscient 2019, Sydney (Australia), Series C	Provider of AI-powered brain mapping and analysis platform	$60M	Base Capital & 4 others	49/100
10th	Jvion 2011, Suwanee (United States), Acquired	Provider of a deep learning-based solution for predicting illness	$11.1M	JMI Management, Trinity Health & 7 others	46/100